Published in Br J Clin Pharmacol on January 01, 1989
Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci (1970) 5.21
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos (1987) 1.70
Vascular selectivity of felodipine. Drugs (1985) 1.62
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm (1985) 1.36
Felodipine kinetics in healthy men. Clin Pharmacol Ther (1985) 1.35
Acute diuretic/natriuretic properties of felodipine in man. Drugs (1985) 1.20
Treatment of essential hypertension with felodipine in combination with a diuretic. Eur J Clin Pharmacol (1986) 1.10
Renal and cardiovascular effects of acute and chronic administration of felodipine to SHR. Eur J Pharmacol (1985) 1.07
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm (1984) 1.03
Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasma. J Chromatogr (1987) 0.96
The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. Br J Clin Pharmacol (1986) 0.91
Place of calcium antagonists in antihypertensive therapy: introduction and round-table discussion. J Cardiovasc Pharmacol (1984) 0.90
Absorption, distribution and elimination of felodipine in man. Drugs (1985) 0.88
Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin Pharmacokinet (1988) 0.86
Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin Invest Med (1987) 0.85
Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers. Drugs (1987) 0.82
Calcium entry blockers for systemic hypertension. Am J Cardiol (1987) 0.80
Clinical evaluation of felodipine in patients with refractory hypertension. Drugs (1987) 0.77
Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics. Eur J Clin Pharmacol (1975) 3.19
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm (1974) 2.18
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet (1976) 2.12
A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) (1975) 2.01
Report of the Radionuclides in Nephrourology Committee on renal clearance. J Nucl Med (1996) 1.98
Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet (1981) 1.94
Renal protective effect of enalapril in diabetic nephropathy. BMJ (1992) 1.88
Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. J Nucl Med (1996) 1.87
Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) (1975) 1.82
Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects. Eur J Clin Pharmacol (1983) 1.73
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos (1987) 1.70
Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) (1986) 1.65
Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol (Copenh) (1975) 1.64
Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ (1990) 1.62
Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest (1981) 1.60
Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) (1975) 1.57
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med (1989) 1.53
Withdrawal symptoms in workers exposed to nitroglycerine. Br J Ind Med (1968) 1.53
Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther (1992) 1.52
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens (1992) 1.48
A sensitive method for the determination of plasma catecholamines using liquid chromatography with electrochemical detection. Life Sci (1978) 1.45
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther (1975) 1.44
Captopril effect on hypertension in patient with renin-producing tumour. Lancet (1979) 1.42
Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron (1993) 1.42
Hyperlipoproteinaemia in renal failure: pathogenesis and perspectives for intervention. Nephrol Dial Transplant (1993) 1.41
The effects of intra-arterially administered propranolol and H 56-28 on blood flow in the forearm--a comparative study of two beta-adrenergic receptor antagonists. Acta Pharmacol Toxicol (Copenh) (1967) 1.40
Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension. Am J Hypertens (1992) 1.39
Blunted renal sodium excretion during acute saline loading in normotensive men with positive family histories of hypertension. Am J Hypertens (1991) 1.39
Consensus on diuresis renography for investigating the dilated upper urinary tract. Radionuclides in Nephrourology Group. Consensus Committee on Diuresis Renography. J Nucl Med (1996) 1.37
Felodipine kinetics in healthy men. Clin Pharmacol Ther (1985) 1.35
Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol (1995) 1.34
Urinary concentration test with desmopressin. Br Med J (1978) 1.34
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant (1997) 1.33
Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther (1985) 1.30
Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens (2000) 1.26
Renal function and biopsy findings in patients on long-term lithium treatment. Kidney Int (1981) 1.24
Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62. Eur J Clin Pharmacol (1978) 1.24
Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet (1994) 1.21
Malignant hypertension--improving prognosis in a rare disease. Acta Med Scand (1979) 1.21
Hemodynamic effects of propranolol and H 56-28 in man--comparative study of two beta-adrenergic receptor antagonists. Acta Pharmacol Toxicol (Copenh) (1967) 1.19
GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant (1998) 1.19
The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease. Eur Heart J (1983) 1.17
The stability of noradrenaline in infusion solutions. Acta Pharmacol Toxicol (Copenh) (1967) 1.17
Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant (1994) 1.17
The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. Br J Clin Pharmacol (1982) 1.17
Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers. Int J Clin Pharmacol Ther Toxicol (1980) 1.17
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Effects of captopril in Bartter's syndrome. N Engl J Med (1981) 1.14
Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet (1980) 1.13
Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol (1997) 1.12
Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. Br Med J (1975) 1.11
Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. Eur J Clin Pharmacol (1992) 1.11
Influence of metoprolol and propranolol on hemodynamic effects induced by physical work and isoprenaline. Acta Pharmacol Toxicol (Copenh) (1975) 1.09
Felodipine, an arteriolar dilator with pronounced antihypertensive effect. Lancet (1983) 1.07
Increased sympathetic nerve activity in renovascular hypertension. Circulation (1999) 1.06
Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol (1985) 1.05
Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet (2007) 1.04
Lithium-induced uraemia. Lancet (1979) 1.03
Potency and time effect relationship in man of propranolol and H 56-28. I. Comparative studies after intravenous administration. II. Studies on the ratio of equipotent oral and intravenous doses. Acta Pharmacol Toxicol (Copenh) (1967) 1.03
The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol (1998) 1.02
The role of beta-1-adrenoceptors in the renin release response to graded renal sympathetic nerve stimulation. Pflugers Arch (1980) 1.01
Renal function in normo- and hypertensive 50-year-old males. Acta Med Scand (1976) 1.00
Metoprolol excretion into breast milk. Br J Clin Pharmacol (1980) 0.98
Expert working group report on nutrition in adult patients with renal insufficiency (Part 2 of 2). Clin Nutr (2000) 0.97
Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clin Pharmacol Ther (1975) 0.96
Absorption of alprenolol in man from tablets with different rates of release. Acta Pharm Suec (1971) 0.96
Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron (1984) 0.95
Physical activity, physical fitness and risk of myocardial infarction. Adv Cardiol (1976) 0.95
Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sci (1974) 0.95
Autoantibodies against cardiac G-protein-coupled receptors define different populations with cardiomyopathies but not with hypertension. Clin Immunol Immunopathol (1994) 0.95
Renin secretion in advanced diabetic nephropathy. Scand J Urol Nephrol Suppl (1984) 0.94
Renal and hemodynamic effects of isradipine in essential hypertension. Am J Med (1989) 0.94
Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant (1994) 0.93
Serum lipids and lipoproteins during long-term administration of an oral contraceptive. Lancet (1966) 0.93
Treatment of renovascular hypertension: one year results of renal angioplasty. Kidney Int (1995) 0.93
Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol (1998) 0.92